{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:11:36Z","timestamp":1748319096192,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard treatment for relapsed diffuse large B cell lymphoma (DLBCL). The BEAM regimen is widely used, but the MEAM regimen is more common in Japan due to the unavailability of carmustine. This retrospective analysis evaluated the efficacy of the thiotepa and busulfan (TT\/BU) regimen compared with other regimens in 27 patients with systemic DLBCL who underwent ASCT at our institution from December 2013 to March 2022. Fourteen patients received the TT\/BU regimen, while 13 received alternative regimens. The TT\/BU regimen demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to other regimens, with a 3\u00a0year PFS of 84.4% and OS of 91.7%. The TT\/BU group also had fewer severe adverse events, particularly regarding renal function. Our findings suggest that the TT\/BU regimen is a well-tolerated and effective alternative for relapsed\/refractory DLBCL and provide valuable insights for future treatment strategies.<\/jats:p>","DOI":"10.1007\/s12185-025-03946-w","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T15:41:26Z","timestamp":1739374886000},"page":"813-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the thiotepa\u2013busulfan conditioning regimen as for autologous stem cell transplantation in relapsed\/refractory systemic diffuse large B cell lymphoma: a single-center retrospective study"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4502-6179","authenticated-orcid":false,"given":"Katsuhiro","family":"Io","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunta","family":"Kakihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"23","key":"3946_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/nejm199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135. https:\/\/doi.org\/10.1056\/nejm199512073332305.","journal-title":"N Engl J Med"},{"issue":"21","key":"3946_CR2","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918\u201327. https:\/\/doi.org\/10.1200\/JCO.2003.10.023.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3946_CR3","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614\u201320. https:\/\/doi.org\/10.1200\/JCO.2007.15.5358.","journal-title":"J Clin Oncol"},{"issue":"27","key":"3946_CR4","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3946_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","volume":"34","author":"EH Wang","year":"2004","unstructured":"Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transpl. 2004;34(7):581\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1704637.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"3946_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2169\/internalmedicine.48.1295","volume":"48","author":"KC Kawabata","year":"2009","unstructured":"Kawabata KC, Hagiwara S, Takenouchi A, Tanimura A, Tanuma J, Tachikawa N, et al. Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases. Intern Med. 2009;48(2):111\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.48.1295.","journal-title":"Intern Med"},{"issue":"9","key":"3946_CR7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00277-016-2740-9","volume":"95","author":"M Sugimoto","year":"2016","unstructured":"Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95(9):1513\u20139. https:\/\/doi.org\/10.1007\/s00277-016-2740-9.","journal-title":"Ann Hematol"},{"issue":"6","key":"3946_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93(6):729\u201335. https:\/\/doi.org\/10.1002\/ajh.25077.","journal-title":"Am J Hematol"},{"issue":"1","key":"3946_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","volume":"19","author":"M Blanes","year":"2013","unstructured":"Blanes M, Lahuerta JJ, Gonzalez JD, Ribas P, Solano C, Alegre A, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transpl. 2013;19(1):69\u201374. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.009.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3946_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106689","volume":"110","author":"J Sapelli","year":"2021","unstructured":"Sapelli J, Filho JS, Matias Vieira GM, Moura FL, Germano JN, de Lima VCC. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. Leuk Res. 2021;110: 106689. https:\/\/doi.org\/10.1016\/j.leukres.2021.106689.","journal-title":"Leuk Res"},{"issue":"10","key":"3946_CR11","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mds059","volume":"23","author":"B Kasenda","year":"2012","unstructured":"Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2013a long-term follow-up study. Ann Oncol. 2012;23(10):2670\u20135. https:\/\/doi.org\/10.1093\/annonc\/mds059.","journal-title":"Ann Oncol"},{"issue":"16","key":"3946_CR12","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/cncr.30695","volume":"123","author":"Z DeFilipp","year":"2017","unstructured":"DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017;123(16):3073\u20139. https:\/\/doi.org\/10.1002\/cncr.30695.","journal-title":"Cancer"},{"issue":"10","key":"3946_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823\u201333. https:\/\/doi.org\/10.1200\/JCO.18.00306.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3946_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.bbmt.2019.01.020","volume":"25","author":"E Kondo","year":"2019","unstructured":"Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the japan society for hematopoietic cell transplantation registry. Biol Blood Marrow Transpl. 2019;25(5):899\u2013905. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.020.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"3946_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bmt.2011.74","volume":"47","author":"S Ganguly","year":"2012","unstructured":"Ganguly S, Jain V, Divine C, Aljitawi O, Abhyankar S, McGuirk J. BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin\u2019s disease. Bone Marrow Transpl. 2012;47(2):311\u20132. https:\/\/doi.org\/10.1038\/bmt.2011.74.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"3946_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/bmt.2015.273","volume":"51","author":"L Sellner","year":"2016","unstructured":"Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transpl. 2016;51(2):212\u20138. https:\/\/doi.org\/10.1038\/bmt.2015.273.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"3946_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"3946_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12185-021-03263-y","volume":"115","author":"M Nishikori","year":"2022","unstructured":"Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022;115(3):391\u20138. https:\/\/doi.org\/10.1007\/s12185-021-03263-y.","journal-title":"Int J Hematol"},{"issue":"13","key":"3946_CR19","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127(13):1642\u20139. https:\/\/doi.org\/10.1182\/blood-2015-10-636340.","journal-title":"Blood"},{"issue":"11","key":"3946_CR20","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510\u201323. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3946_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","volume":"23","author":"M Scordo","year":"2017","unstructured":"Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, et al. A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning. Biol Blood Marrow Transpl. 2017;23(1):38\u201343. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.024.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"3946_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.bbmt.2018.04.013","volume":"24","author":"M Scordo","year":"2018","unstructured":"Scordo M, Morjaria SM, Littmann ER, Bhatia A, Chung HH, Maloy M, et al. Distinctive infectious complications in patients with central nervous system lymphoma undergoing thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(9):1914\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.013.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"3946_CR23","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","volume":"4","author":"E Schorb","year":"2020","unstructured":"Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378\u201381. https:\/\/doi.org\/10.1182\/bloodadvances.2020002064.","journal-title":"Blood Adv"},{"issue":"5","key":"3946_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12185-020-03007-4","volume":"112","author":"F Wada","year":"2020","unstructured":"Wada F, Nishikori M, Hishizawa M, Watanabe M, Aiba A, Kitano T, et al. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. Int J Hematol. 2020;112(5):609\u201313. https:\/\/doi.org\/10.1007\/s12185-020-03007-4.","journal-title":"Int J Hematol"},{"key":"3946_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967026","volume":"13","author":"X Wei","year":"2022","unstructured":"Wei X, Xie Y, Jiang R, Li H, Wu H, Zhang Y, et al. The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: a real-world study. Front Immunol. 2022;13: 967026. https:\/\/doi.org\/10.3389\/fimmu.2022.967026.","journal-title":"Front Immunol"},{"issue":"10343","key":"3946_CR26","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6.","journal-title":"Lancet"},{"issue":"7","key":"3946_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/nejmoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339. https:\/\/doi.org\/10.1056\/nejmoa2116596.","journal-title":"N Engl J Med"},{"issue":"9","key":"3946_CR28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2021013289","volume":"139","author":"M Shadman","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139(9):1330\u20139. https:\/\/doi.org\/10.1182\/blood.2021013289.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03946-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:32:18Z","timestamp":1748259138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03946-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3946"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03946-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}